Protective effects of beta-casomorphin-7 on renal injury in a rat model with streptozotocin-induced diabetic nephropathy

doi:10.3969/j.issn.2095-4344.2016.05.016

Abstract

Abstract:

BACKGROUND: Studies have found that β-casomorphin 7 can lessen oxidation of renal tubular epithelial cells and lower blood sugar in a rat model of diabetes. There is a few studies concerning the effect of β-casomorphin-7 on diabetic nephropathy.
OBJECTIVE: To explore the effects of β-casomorphin-7 on renal injury in a rat model of diabetic nephropathy.
METHODS: The 30 rats were equally and randomly divided into control group, model group and β-casomorphin-7 group. Twenty rat models of diabetes were established. In the model and β-casomorphin-7 groups, rats were intraperitoneally injected with streptozotocin (60 mg/kg). In the control group, rats were intraperitoneally injected with an equal volume of citric acid. Rats in the β-casomorphin-7 group were intragastrically administered β-casomorphin-7 for 30 days. Rats in the model and control groups were given an equal volume of saline by intragastric administration.
RESULTS AND CONCLUSION: (1) Compared with the control group, insulin levels decreased, glucagon, blood glucose, urine glucose, urine protein, serum creatinine, serum urea nitrogen levels, mRNA and protein expression levels of type I collagen and type IV collagen in kidney increased in the model group. (2) Compared with the model group, above indexes were apparently recovered in the β-casomorphin-7 group. These findings indicate that β-casomorphin-7 has a protective effect on renal injury in diabetic nephropathy rats.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Gao Yan, Yuan Lu-liang, Zhang Hai-song. Protective effects of beta-casomorphin-7 on renal injury in a rat model with streptozotocin-induced diabetic nephropathy[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(5): 701-706.

Figures/Tables 7

References

[1] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12): 1090-1101.
[2] American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011;34 Suppl 1:S11-61.
[3] 范英兰.β-酪啡肽-5对糖尿病大鼠血糖和氧化应激的影响[D].南京:南京农业大学,2010.
[4] Yin H, Miao J, Zhang Y. Protective effect of beta-casomorphin-7 on type 1 diabetes rats induced with streptozotocin. Peptides. 2010;31(9):1725-1729.
[5] Somania R, Singhai AK, Shivgunde P, et al. Asparagus racemosus Willd (Liliaceae) ameliorates early diabetic nephropathy in STZ induced diabetic rats. Indian J Exp Biol. 2012;50(7):469-475.
[6] Han DN, Zhang DH, Wang LP, et al. Protective effect of β-casomorphin-7 on cardiomyopathy of streptozotocin- induced diabetic rats via inhibition of hyperglycemia and oxidative stress. Peptides. 2013;44:120-126.
[7] Yin H, Miao J, Ma C, et al. β-Casomorphin-7 cause decreasing in oxidative stress and inhibiting NF-κB-iNOS-NO signal pathway in pancreas of diabetes rats. J Food Sci. 2012;77(2):C278-282.
[8] 张景云.结缔组织生长因子在糖尿病肾病发病中的作用及己酮可可碱对其表达影响的研究[D].天津:天津医科大学,2007.
[9] Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288(2):F399-405.
[10] Ma YY, Sun D, Li J, et al. Transplantation of endothelial progenitor cells alleviates renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction. Life Sci. 2010;86 (21-22): 798-807.
[11] 王华.糖尿病肾病的饮食探讨[J].中国误诊学杂志,2011,11(11): 2603.
[12] 中国医师协会内分泌代谢科医师分会.2 型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识[J].中国糖尿病杂志,2013,21(10):865-870.
[13] 方燕红.硝苯地平联合贝那普利治疗糖尿病肾病的临床观察[J].中国药房,2011,(40):3802-3803.
[14] 叶俊鹏,黄培良,赖瑞平.门诊常用降血脂药物的用药分析[J].现代医院,2013,13(12):65-67.
[15] 李建国,胡齐鸣,张宝霞,等.益气养阴收敛固涩方治疗气阴两虚型糖尿病肾病30例临床观察[J].实用中西医结合临床, 2014,14(3): 77-78.
[16] 郭彦军.益肾化瘀方治疗糖尿病肾病疗效观察[J].陕西中医, 2013, 34(8):954 -955.
[17] 蒋丙义.血府逐瘀汤治疗43 例糖尿病肾病临床效果观察[J].基础医学论坛,2014,18(14):1854-1855.
[18] 金秀名.血液透析与腹膜透析治疗糖尿病肾病的疗效观察[J].中国实用医药,2014,9(1):118-119.
[19] 陆翰澜,陈瑜,傅尚希,等.亲属活体肾移植后供者安全性评价[J].中国组织工程研究,2013,17(44):7681-7686.
[20] Lo CS, Liu F, Shi Y, et al. Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen- transgenic mice. Am J Physiol Renal Physiol. 2012;302(7): F840-852.
[21] Nadarajah R, Milagres R, Dilauro M, et al. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int. 2012; 82(3):292-303.
[22] Mori J, Patel VB, Ramprasath T, et al. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol. 2014;306(8):F812-821.
[23] Lakshmanan AP, Thandavarayan RA, Watanabe K, et al. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin- induced diabetic mice. Mol Cell Endocrinol. 2012;348(1): 104-111.
[24] Fernandez Juarez G, Luño J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61(2):211-218.
[25] Sasai Y, Iwakawa K, Yanagida K, et al. Advanced glycation endproducts stimulate renal epithelial cells to release chemokines that recruit macrophages, leading to renal fibrosis. Biosci Biotechnol Biochem. 2012;76(9):1741-1745.
[26] Ishibashi Y, Matsui T, Takeuchi M, et al. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res. 2012;44(12):891-895.
[27] Zhang MH, Feng L, Zhu MM, et al. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol. 2014;151(1):591-600.
[28] Sedeek M, Gutsol A, Montezano AC, et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond). 2013;124(3):191-202.
[29] Eid AA, Ford BM, Bhandary B, et al. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes. 2013;62(8):2935-2947.
[30] Abdillahi M, Ananthakrishnan R, Vedantham S, et al. Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2012;303(3):H297-308.
[31] Oudot C, Lajoix AD, Jover B, et al. Oxydative stress and beneficial effect of sodium restriction on kidney damage associated with insulin resistance in rats. Ann Cardiol Angeiol (Paris). 2012;61(3):162-166.

[32] Hellemons ME, Kerschbaum J, Bakker SJ, et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med. 2012;29(5):567-577.
[33] Bryan HK, Olayanju A, Goldring CE, et al. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013;85(6): 705-717.
[34] Li Y, Paonessa JD, Zhang Y. Mechanism of chemical activation of Nrf2. PLoS One. 2012;7(4):e35122.
[35] Wang F, Tian F, Whitman SA, et al. Regulation of transforming growth factor β1-dependent aldose reductase expression by the Nrf2 signal pathway in human mesangial cells. Eur J Cell Biol. 2012;91(10):774-781.
[36] Soetikno V, Sari FR, Lakshmanan AP, et al. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res. 2013;57(9):1649-1659.
[37] Nakagawa T, Sato W, Kosugi T, et al. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res. 2013;2013:184539.
[38] Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol. 2012;32(4):385-393.
[39] Schlingemann RO, Van Noorden CJ, Diekman MJ, et al. VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care. 2013;36(6):1629-1634.
[40] Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23(3):507-515.
[41] Xu XX, Qi XM, Zhang W, et al. Effects of total glucosides of paeony on immune regulatory toll-like receptors TLR2 and 4 in the kidney from diabetic rats. Phytomedicine. 2014;21(6): 815-823.
[42] Kaur H, Chien A, Jialal I. Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol. 2012;303(8):F1145-1150.
[43] Xie X, Peng J, Chang X, et al. Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol. 2013;369(1-2):86-97.
[44] Verzola D, Cappuccino L, D’Amato E, et al. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int. 2014;86(6):1229-1243.
[45] Han DN, Zhang DH, Wang LP, et al. Protective effect of β-casomorphin-7 on cardiomyopathy of streptozotocin- induced diabetic rats via inhibition of hyperglycemia and oxidative stress. Peptides. 2013;44:120-126.